James Hardie Industries Plc - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by James Hardie Industries Plc, a foreign private issuer, for the month of February 2018. The report was signed on February 8, 2018, by Natasha Mercer, Company Secretary. The filing primarily serves to distribute a press release (Exhibit 99.1) dated February 7, 2018, and includes standard forward-looking statement disclosures.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document acts as a cover for an external exhibit and contains no embedded financial tables or quantitative performance data.
Material Changes
No material changes to financial results or operations are detailed within the text of this filing. The document references the "consummation of the Fermacell acquisition" as a risk factor and forward-looking topic but does not provide specific details on the status or financial impact of this transaction in this text.
Guidance, Outlook, and Risks
The filing contains extensive forward-looking statements regarding future performance, capital expenditures, credit facilities, dividend payments, and share buy-backs. Key risks and contingencies identified include:
- Asbestos Liabilities: Risks related to prior asbestos product manufacture, contributions to the Asbestos Injuries Compensation Fund (AICF), potential shortfalls in the fund, and currency exchange impacts on asbestos liabilities.
- Legal and Regulatory: Exposure to product liability, environmental, and consumer class action proceedings, as well as changes in tax laws.
- Market Conditions: Dependence on US and Asia Pacific housing markets, new home construction levels, consumer confidence, and raw material costs.
- Operational Risks: Integration of the Fermacell acquisition, plant closures, and reliance on a concentrated customer base.
Investor Verification Checklist
- Review Exhibit 99.1 (Appendix 3X P Lisboa 7 February 2018) for the specific content of the press release referenced in this filing.
- Verify the current status and financial impact of the Fermacell acquisition integration.
- Monitor updates regarding the Asbestos Injuries Compensation Fund (AICF) and any required contributions or shortfalls.
- Check subsequent filings for specific financial results, as this 6-K does not contain quantitative data.